J&J Seeks Indian Drug Regulator's Nod For Phase 3 Trials Of Its Single-Dose COVID-19 Vaccine, Import License: Report(A picture of vaccine vials from Johnson and Johnson)

In a major positive development that could go on to boost vaccine availability in the country, United States (US) based pharmaceutical giant Johnson & Johnson (J&J) is said to have applied to the Indian drug regulator, seeking permission to conduct third phase trials of its single-dose COVID-19 vaccine in India and to secure an import licence, reports Economic Times.

The company has reportedly also sought an early meeting of the the Drug Controller General of India's (DCGI) subject expert committee (SEC) on COVID-19 to take up its application.

The development comes after the government had recently fast-tracked the emergency approvals for all foreign-produced vaccines that have been given a similar nod by the World Health Organization (WHO) or regulators in the United States (US), the United Kingdom (UK), Europe, or Japan.

If approved, J&J's vaccine will be the first single-dose vaccine in India, as the other three, Covishield, Covaxin and Sputnik V, which have been approved for administration so far are all two-dose vaccines.

The development also gains significance as it comes the very day when the government decided to expand the nationwide COVID-19 vaccination drive by allowing everyone above 18 years of age to be vaccinated from 1 May.

The government has also permitted the state governments, private hospitals and industrial establishments to procure the doses directly from manufacturers.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber